Extended immunosuppression with cyclophosphamide using controlled-release polymeric implants

Ormrod, Douglas; Cawley, S.; Miller, Thomas E.

doi:10.1016/0192-0561(85)90062-1

Cited by 5 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antibiotics incorporated into bone cement have also been used therapeutically in the treatment of chronic bone sepsis [19], and deep muscle and skeletal infections [20]. More recently we have 241 used this polymeric carrier to deliver cyclophosphamide and achieved improved pharmacokinetics, extended immunosuppression and decreased toxicity [11]. Synthetic analogs of corticosteroids are potent drugs which can be used to regulate many physiological and pathological processes.…”

Section: Discussionmentioning

confidence: 99%

“…Finally, as the reservoir is depleted, withdrawal from corticosteroid is gradual and thus the development of side effects may be avoided. It should also be noted that the pharmacokinetics of drugs administered in bone cement can also be manipulated by altering the shape, size and composition of the implants [11]. Using rat heart allograft survival as an index, Provoost et al [3] have compared the effect of daily injections of prednisolone with continuous subcutaneous infusion using mini-osmotic pumps.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Sustained release of a corticosteroid using polymeric implants

et al. 1986

View full text Add to dashboard Cite

An effective sustained release method of drug administration, using methylprednisolone incorporated into acrylic bone cement, has been developed. The effect of this form of treatment on peripheral blood leukocytes, lymphoid tissue weight and the inflammatory response has been evaluated. This mode of methylprednisolone administration was compared with conventional systemic therapy and was found to produce rapid and prolonged pharmacological effects at very low plasma levels of drug. A dose response relationship was established and we determined that, for a given quantity of drug, the level and duration of suppression was greater using sustained release therapy. The inflammatory response was also depressed using this mode of administration. These results, coupled with the commercial availability and existing clinical approval of SIMPLEX P bone cement, suggest that further development may lead to useful clinical protocols.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Sustained release of a corticosteroid using polymeric implants

et al. 1986

View full text Add to dashboard Cite

show abstract

“…A slow release method, utilising surgical bone cement as a polymeric carrier, was used to administer cyclophosphamide. The technique has previously been described in detail (Ormrod et al, 1985). Varying numbers of subcutaneously implanted bone cement disks, each containing cyclophosphamide (Endoxan-Asta, Asta-Werke AG, Bielefeld, West Germany) 75 mg, were implanted into animals to achieve graded cytodepletion.…”

Section: Cyclophosphamide Administrationmentioning

confidence: 99%

Exacerbation of experimental pyelonephritis by cyclosporin A

Miller¹,

Findon²

1988

Journal of Medical Microbiology

View full text Add to dashboard Cite

An athymic rat strain lacking functional T cells was used to assess the role of cell-mediated immunity (CMI) in host defence against renal infection. CMI was ruled out as a relevant host defence component, but when cyclosporin A (CsA) was administered to athymic animals, renal infection was exacerbated. CsA is thought to affect T lymphocyte function and, in the absence of a target cell, cellular defences in the athymic animal were not expected to be compromised by CsA. An effect on noncellular defence mechanisms was therefore considered but our studies did not support this explanation-rather they indicated a depression of either cellular defences or of a specific cellular component. The present experiments have provided additional information on the relationship between CsA administration and the depression of host defence mechanisms but further studies will be necessary to identify the components affected.

show abstract

Slow release of anticancer drugs from porous calcium hydroxyapatite ceramic

Uchida

Shinto

Araki

et al. 1992

Journal Orthopaedic Research

142

View full text Add to dashboard Cite

We have developed a new delivery system for sustained release of an anticancer drug (cis-platinum) by enclosure into blocks of porous calcium hydroxyapatite ceramic. The slow release of this drug from this system was confirmed in in vitro experiments. When this system was implanted into normal back muscle, or the tibia, sustained release of cis-platinum was observed during a 12-week period after implantation. The diffusion rate of cis-platinum into blood and other organs (liver, kidney, brain) was less than 10% of that at the implanted site. This delivery system placed into experimental tumors of mice also showed a uniform release of anticancer drug for more than 3 months. Inhibition of tumor growth was more marked after local implantation of this system than after intraperitoneal administration of cis-platinum. These results indicate that this new approach to a drug delivery system may well have an important role in cancer chemotherapy. In bone tumors it is attractive because the mechanical strength of calcium hydroxyapatite ceramic permits partial surgical excision and replacement of the bone defect at the same time.

show abstract

Extended immunosuppression with cyclophosphamide using controlled-release polymeric implants

Cited by 5 publications

References 3 publications

Sustained release of a corticosteroid using polymeric implants

Sustained release of a corticosteroid using polymeric implants

Exacerbation of experimental pyelonephritis by cyclosporin A

Slow release of anticancer drugs from porous calcium hydroxyapatite ceramic

Contact Info

Product

Resources

About